<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>19543565</identifier>
<setSpec>0327-6139</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Bustin, Julián</dc:author>
<dc:description xml:lang="en">The Clinical Antipsychotic Trials of Intervention Effectiveness -Alzheimer Disease (CATIE-AD) is the first 36 weeks effectiveness trial of atypical antipsychotics in patients with Alzheimer's disease presenting with behavioral and psychiatric symptoms of dementia (BPSD). There were no significant differences between atypical antipsychotics and placebo in effectiveness measures which also included a cost-benefit analysis. This article not only reviews this landmark study but also summarizes the complex relationship between antipsychotics and BPSD during the last years.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2009 Mar-Apr </dc:date>
<dc:title xml:lang="es">Antipsicóticos atípicos y el CATIE-AD. ¿Un antes y un después?</dc:title>
<dc:title xml:lang="en">[Atypical antipsychotics and CATIE-AD. Is this a turning point?].</dc:title>
<dc:publisher>Vertex (Buenos Aires, Argentina)</dc:publisher>
</metadata>
</record>
</pubmed-document>
